Sickle cell disease (SCD) is a widespread genetic haemoglobin disorder, with 2Á28 per 1000 conceptions affected worldwide. Its highest prevalence is observed in sub-Saharan Africa, where 233 000 children are born with SCD every year compared to 43 000 per year in all other regions of the world combined. In high-income countries, the life expectancy of patients with SCD is estimated to be more than 50 years, whereas in sub-Saharan Africa many affected children die before reaching adulthood (Modell & Darlison, 2008) . However, the survival of African patients with SCD is progressively increasing due to improved access to health care (Akinyanju et al, 2005; Modell & Darlison, 2008; Tluway & Makani, 2017 ). An increasing number of children and teenagers will, therefore, be at risk of both acute vaso-occlusive complications and chronic organ damage.
Growth impairment is another well-known complication in children with SCD, initially reported in numerous countries (Jamaica (Ashcroft et al, 1972; Stevens et al, 1986; Singhal et al, 1994 Singhal et al, , 1996 , USA (Platt et al, 1984) , Brazil (Zago et al, 1992) ) over 30 years ago, and described as more severe in patients with HbSS (SS) or Hb Sb 0 (Sb 0 ) phenotype compared to patients with HbSC (SC) or HbSb + (Sb + ) phenotype in the USA (Phebus et al, 1984) . More recently, specific height and weight reference curves have been established in Jamaica (Thomas et al, 2000) . Growth retardation, which is frequently associated with delayed puberty, probably results from multiple factors, including undernutrition, endocrine disorders (such as inadequate production of testosterone and growth hormone), and increased basal metabolic rate due to chronic anaemia (Odonkor, 1983) . Several complications due to growth failure and underweight have been reported, such as psychological impacts, low bone density (Meeuwes et al, 2013) , and cognitive deficits (Puffer et al, 2010) . Currently, it is unknown if growth failure either results from or has an impact on the frequency of vaso-occlusive crises and chronic SCD-related organ damage. Recent studies in high-income countries have shown that underweight tends to decline in patients with SCD (Chawla et al, 2013) . This is thought to be the result of both hygiene and dietary modifications (Hyacinth et al, 2013; Adegoke et al, 2017) and disease-modifying treatments [i.e. hydroxycarbamide (Hankins et al, 2005) , chronic transfusion programmes ]. In sub-Saharan Africa, these modern treatments are unfortunately not yet widely available. Considerable effort is made to educate the parents of children with SCD followed in SCD centres and prevent infectious diseases through vaccinations. Such interventions have already led to a dramatic improvement in survival. However, data concerning growth impairment in African patients with SCD rely on small sample size (Esezobor et al, 2016; Odetunde et al, 2016) or outdated studies (Ebomoyi et al, 1989) .
Thus, in order to determine the prevalence and factors correlated with growth failure in patients with SCD in subSaharan Africa, we studied a large cohort of patients in Mali, Senegal, Cameroon, Gabon and the Ivory Coast.
Methods

Material and methods
We performed a case-control cross-sectional study nested in the Coeur, Art eres et DREpanocytose (i.e. Heart, Arteries and Sickle Cell Disease) (CADRE) cohort, a multinational cohort of patients with SCD and controls conducted in sub-Saharan Africa (Ranque et al, 2014) . In the CADRE cohort, patients with SCD aged 5 years old and over were recruited through outpatient clinics in Yaound e (Cameroon), Douala (Cameroon), Dakar (Senegal), Abidjan (Ivory Coast), Franceville (Gabon) and Bamako (Mali). Medical appointments were scheduled at a steady state (no vasoocclusive crisis for the last 15 days, no infectious disease for the last 8 days and no transfusion for the preceding 3 months). Healthy controls were enrolled to obtain normal ranges of biological and functional measures in this west and central African population. Healthy controls were siblings of the patients with SCD, members of the centre's medical or nursing staff or their children. In each centre, except for Gabon, we ensured there was sufficient healthy controls (more than 20) in each 5-years age group. No control could be recruited in Gabon because of organizational issues. The recruitment of patients and controls took place from February 2011 to December 2013.
Haemoglobin phenotype was confirmed by both alkaline haemoglobin electrophoresis and high performance liquid chromatography in patients with SCD in all centres except in Gabon, where only alkaline haemoglobin electrophoresis was used. Haemoglobin phenotype was confirmed by alkaline haemoglobin electrophoresis for all healthy controls. For each subject, we recorded the level of parental education and patient medical history and clinical features, including weight, height, brachial size and blood pressure. Blood tests included full blood cell count and creatinine levels. Estimated glomerular filtration rate (eGFR) was calculated using the Schwartz formula (Abraham et al, 2009) . Abnormal microalbuminuria was defined as a urine albumin/creatinine ratio >30 mg/g. Lactate dehydrogenase (LDH) and bilirubin were not measured in Gabon and Senegal. Icterus was defined as a bilirubin level >42 lmol/l or, when this information was unavailable, clinical icterus.
Echocardiographic measures were performed according to the current guidelines of the American Society of Echocardiography. Pulmonary hypertension was defined by tricuspid regurgitation jet velocity of more than 2Á5 m/s (Reeves et al, 2007) . Parents' level of education was assessed and used as an estimation of social class and family income. Level of education was noted as secondary or higher education if at least one of the two parents had secondary or upper level schooling.
A more detailed design of the study is available in the primary report of the CADRE study (Ranque et al, 2016) . The study was approved by the national ethics committee in each of the participating countries (N043/MSLS/CNER-dkn, N18 MS-SG-CNESS/2011, N12/40 MSAS/DS/CNERS, N016-CNE-SE-2011 and N023-CNER-GB_2011).
The main outcome of our study was growth failure, defined as a height and/or weight and/or body mass index (BMI) 89 (23) 79 (17) 85 (15) 106 (19) 110 (13) 124 (16) eGFR, ml/min; median (
Leucocyte count,
12 (11Á7) 17 (19Á1) 46 (18Á7) 65 ( ; more severe phenotypes) and SC and Sb + (SC-Sb + ; less severe phenotypes).
Statistical analysis
We described the frequency of growth failure and of other clinical and biological parameters according to the phenotypic group. Patients with and without growth failure were compared using Chi square, Fisher or Wilcoxon tests as appropriate. We also looked for independent associations between growth failure and the patients' clinical and biological characteristics using multivariate logistic regression, with adjustment for age group, country, sex, haemoglobin phenotype and parents' level of education. We checked the log linearity hypothesis. If it was refuted, the variables were categorized according to quartiles. The LDH level was adjusted for the laboratory standards of each centre. Because LDH level was not measured during the first 6 months of the study, 33% of LDH values were imputed using multiple imputations with full conditional specifications. Detailed methods for imputations were reported by Dubert et al (2017) . All statistical analysis was performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).
Results
A total of 2583 subjects, including 1799 SS, 114 Sb 0 , 287 SC, 96 Sb + patients and 287 healthy controls were enrolled in Cameroon (n = 735), Ivory Coast (n = 380), Gabon (n = 298), Mali (n = 589) and Senegal (n = 581). The clinical and biological characteristics of the patients and healthy controls are given in Table I . Overall, median [interquartile range] age was 12 [8-16] years old and males represented 48% of the population. Sixty-five percent of children had at least one parent with a secondary or higher education. Growth failure was diagnosed in 51% of SS, 58% of Sb 0 , 44% of SC, and 38% of Sb + patients versus 32% of controls (P = 0Á004). The frequency of growth failure according to 5 age groups, sex and phenotypic group is given in Fig 1. The difference in growth failure rate between patients and healthy controls was most significant in 15-to 17-year-old males: in this age group, growth failure was diagnosed in 74% of SSSb 0 males, 36% of SC-Sb + males, and 11% of controls (P < 0Á001). The characteristics of patients with SCD with and without growth failure are given in Table II . In univariate analysis, growth failure was significantly associated with phenotypic group (P = 0Á004), male sex, lower education of parents, [12] [13] [14] years age group, lower blood pressure, higher leucocyte count, lower haemoglobin rate, icterus and country of origin (P < 0Á001 for all criteria).
Multivariate analysis with adjustment for age, sex, country, SCD phenotype and parents' level of education showed that growth failure in patients with SCD was most frequent in the [12-14] years age group [OR = 2Á31, 95% confidence interval (CI) = 1Á75-3Á07 compared with (5-8) years age group]. 12 (25) 4 (14Á3) 21 (28Á8) 19 (18Á5) NB: Values are reported as n (%), unless otherwise indicated. Mean with standard deviation is used for the normally distributed variables, median with interquartile range is used when the variables have a non-normal distribution. BMI, body mass index; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LDH, lactate dehydrogenase; SCD, sickle cell disease; SD, standard deviation; TRV, tricuspid regurgitation jet velocity. *Primary education: no secondary or higher education for any of the two parents. Secondary education or higher: secondary or higher education for at least one of the parents. Growth failure was associated with parents' primary education compared to secondary or higher education and was also associated with SS (OR = 2Á06, 95% CI = 1Á26-3Á36) or Sb 0 phenotypes (OR = 2Á27, 95% CI = 1Á22-4Á21) versus Sb + phenotype patients, and with icterus. Regarding biological variables, growth failure was negatively associated with haemoglobin level and positively associated with leucocyte count and microalbuminuria. In the multivariate analysis, no association was found between growth failure and history of acute or chronic SCD-related complications, such as vaso-occlusive crisis, acute chest syndrome, osteonecrosis, leg ulcers, priapism, pulmonary hypertension or stroke. Accordingly, there was no association between growth failure and a history of severe bacterial infections such as septicaemia, osteitis or meningitis.
Figure 2 presents median height and BMI according to age group, sex and phenotypic group. In subjects aged 13-15 years, mean height and BMI were significantly lower in children with SCD than in healthy controls, both for males and females. For instance, in males, height and BMI were, respectively, 152 cm and 15Á7 kg/m 2 in SS-Sb 0 , 159 cm and 16Á7 kg/m 2 in SC-Sb + patients versus 172 cm and 21 kg/m 2 in controls (P < 0Á0001 for SS vs. controls and P = 0Á002 for SC vs. controls comparisons). In older male subjects, BMI remained significantly lower in patients with SCD compared to healthy controls. By contrast, BMI did not differ significantly between patients with SCD and controls in female subjects over the age of 17 years. In subjects aged 15-17 years, mean height only differed significantly between controls and SS-Sb 0 male patients. Over the age of 17 years, no difference in height was observed between healthy controls and patients of all phenotypes and sex.
Regarding weight (Fig 3) , 4% of all children were overweight, with a BMI over the 85 th percentile on WHO growth charts. Controls were more frequently overweight (9%), than patients with SCD (3% in SS-Sb 0 patients, 4% in SC-Sb + patients) (P = 0Á0003). In healthy controls, females were more frequently overweight than males [22% vs. 5% in males in the (12-14) years age group], but this gender difference was not observed in patients with SCD. Among patients with SCD, being overweight was only associated with haemoglobin level: mean haemoglobin level was 94 g/l in the overweight group vs. 83 g/l in the normal or underweight group (P < 0Á0001).
Discussion
To our knowledge, our study is the largest to date to assess growth status in patients with SCD and one of the first to look for associations between growth failure, haemoglobin phenotypes and chronic SCD complications in sub-Saharan Africa. In the studied population, living in West and Central Africa, more than half of patients with SS or Sb 0 phenotypes and more than one third of patients with SC or Sb + phenotypes suffered from growth failure. Growth failure was significantly more frequent in SS and Sb 0 phenotypes, whereas it was similar in SC, Sb + phenotypes and healthy subjects, as previously described in different countries (Platt et al, 1984; Stevens et al, 1986; Singhal et al, 1994; Chawla et al, 2013; Lukusa Kazadi et al, 2017) . The greatest difference in growth failure frequency compared to non-SCD controls was observed during adolescence, between 12 and 18 years of age. The weight deficit was more severe than the height deficit, which concurs with previous studies performed in the USA (Platt et al, 1984) and in Nigeria (Ebomoyi et al, 1989) . Both deficits were more profound in males than in females, as previously reported (Phebus et al, 1984; Silva & Viana, 2002; Mitchell et al, 2009) . Mean height was in the normal range in females over the age of 15 years and males over 17 years old. As described by Thomas et al (2000) , the BMI had almost returned to the healthy controls' range in females with SCD older than 17 years, but was still too low in males with SCD of the same age. Because growth delay and puberty delay are often associated (Zemel et al, 2007) and because puberty begins later in males than in females, we could have hypothesized that males' BMI eventually returns to normal a few years later, but it was still not the case in the [19] [20] [21] the proportion of growth retardation that was related to pubertal delay in the teenage population. In our multivariate analysis, the statistical model takes age into account and should thus attenuate the "lag" effect of the puberty delay on growth.
Growth failure in SCD is also believed to be induced by higher energy expenditure (Barden et al, 2000; Buchowski et al, 2002; Rhodes et al, 2009 ) and hypermetabolic state resulting from chronic haemolysis. This hypothesis is consistent with the correlation we observed between growth failure, anaemia and haemolysis markers, and may explain the difference between the SS-Sb 0 and SC-Sb + phenotypes, which display lower (Meeuwes et al, 2013 ) levels of haemolysis (Dubert et al, 2017) . Furthermore, the high frequency of growth failure we observed in African children with SCD contrasts with the most recent studies on growth status of children with SCD in high-income countries. For instance, Chawla et al (2013) found that only 6Á5% of American patients with SCD were underweight and 22% were overweight or obese (even though only 15% of SS-Sb 0 phenotype patients were overweight) versus only 4% in our study. This discrepancy may have several explanations. NB: Values are reported as n (%), unless otherwise indicated. ACS, acute chest syndrome; CI, confidence interval; LDH, lactate dehydrogenase; OR, odds ratio; SCD, sickle cell disease; SD, standard deviation; TRV, tricuspid regurgitant jet velocity; VOC, vaso-occlusive crisis *Growth failure: height, weight or BMI below the 5 th percentile on World Health Organization growth charts. † Multivariate analysis adjusted for parents' level of education, sex, age, and country, plus SCD phenotype for the analysis of association with clinical and biological characteristics and complications. ‡ Primary education: no secondary or higher education for any of the two parents. § In Mali, Cameroon and Ivory Coast only. For the analysis, imputed log-transformed LDH were used. ¶ Urine albumin/creatinine ratio >30 mg/g. k Cardioechographic measures were available in 280 patients. **Severe bacterial infections include meningitis, septicaemia and osteitis.
First, we studied children living in extremely low-income countries, frequently stricken by malnutrition (a major cause of growth delay in patients with SCD; Modebe & Ifenu, 1993) and with a high infectious disease burden. Overweight/ obesity trends in children of the general population are hence very different between the USA and sub-Saharan countries: 41Á8% of American children between 5 and 19 years old were overweight or obese in 2016 versus 9Á6-15Á6% in West and Central Africa (Table SI) (http://www.who.int/gho/ncd/risk_ factors/overweight/en/ [Accessed October 22, 2017]). Unfortunately, we did not assess the nutritional status of our patients, but the high rate of growth failure in non-SCD controls reported here is a fair illustration of the poor socio-economic setting in our study, although we lack statistical power to estimate precisely the rate of growth failure in healthy children due to the limited number of healthy controls in the CADRE cohort. We could not find recent data about growth failure in sub-Saharan African children older than 5 years old. However, the prevalence of underweight (weight below the 5th percentile of WHO standards) in infants of sub-Saharan countries, reported by the WHO (http://apps.who.int/gho/data/node.main.CHILDUN DERWEIGHT?lang=en [Accessed May 29, 2017] ), is consistent with our findings in older healthy controls (Table I,  SII) .
Secondly, sub-Saharan African children with SCD do not have access to the most efficient disease-modifying treatments, namely hydroxycarbamide and long term transfusion programmes, which have been proven efficient in improving growth in children with SCD . Notably, growth failure was less frequent in Cameroon, but this finding is probably due to ethnic-related differences in morphotype. Indeed, Cameroonian subjects are known to have a higher BMI than West African subjects (https://knoema.fr//WHOG DOBMIMay/who-global-database-on-body-mass-index-bmi? country=1000360-cameroon [Accessed April 23, 2018] ) and the difference in growth failure frequency between patients with SCD and country-matched healthy controls was similar to that of other countries (data not shown).
Very few studies have looked at the long-term consequences of SCD related growth retardation. In the USA, Chawla et al (2013) found an association between underweight and priapism, but not with other SCD-related complications. In our study, after accounting for the phenotypic group, we did not find any association between growth failure and SCD-related acute complications, particularly the frequency of vaso-occlusive crises. Neither did we find any association with the history of SCD-related chronic complications except for microalbuminuria, which is an early marker of glomerulopathy. It is worth noting that stroke prevalence is unexpectedly low in our study, which could be explained by different factors, such as mortality bias (hospital access is limited in the countries participating in the CADRE cohort, hence some children who suffer from a severe stroke might have died before being admitted to a hospital), unavailability of cerebral imaging (even overt strokes may be underdiagnosed) or possible lower prevalence of SCD-related strokes in West and Central African regions. The cross-sectional design of our study does not allow conclusions to be drawn about the long-term effects of growth failure on the incidence of complications occurring later in adulthood, such as pulmonary hypertension, heart disease, central nervous system vasculopathy, leg ulcers, retinopathy or osteonecrosis. Moreover, a mortality bias cannot be ruled out, because patients with severe chronic complications may be more likely to die if they are also underweight.
Therefore, the association between SCD-related complications and growth failure was probably underestimated in our study. This potential association will best be assessed during the follow-up of the CADRE cohort.
Conclusion
Growth failure is highly frequent in sub-Saharan children suffering from SCD and is related to weight more so than height. Its prevalence is maximal during adolescence, probably because of puberty delay. Compared to healthy controls, growth failure is more frequent in SS-Sb 0 patients but not in SC-Sb + patients; more frequent in males than in females, in whom BMI, weight and height are normalized by the age of 17 years. In this cross-sectional analysis, growth failure was associated with haemolysis level and microalbuminuria, but not with SCD-related acute and chronic clinical complications.
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